Jasper Therapeutics Investor Relations Material

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of therapeutic agents primarily for hematopoietic stem cell transplantation and gene therapies. The company is focused on advancing novel therapeutic agents intended for a variety of applications, including conditions like chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes. Additionally, Jasper Therapeutics is developing new conditioning regimens for stem cell transplantation and ex-vivo gene therapy, which involves the genetic manipulation of cells outside the body before transplantation. Their leading product candidate, briquilimab, is designed to clear hematopoietic stem cells from bone marrow to facilitate allogeneic stem cell or gene therapy. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.